ASKA Pharmaceutical Holdings Co., Ltd. (4886) AI Stock Analysis

• Market Cap: ¥57.64B
• Dividend Yield: 2.48%
• Average Volume (3M): 49.10K
• Price to Earnings (P/E): 12.1
• Beta (1Y): 0.57
• Revenue Growth: 6.23%
• EPS Growth: -31.45%
• Country: JP
• Employees: 762
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 43.88
• Shares Outstanding: 28,763,199
• 10 Day Avg. Volume: 37,820
• 30 Day Avg. Volume: 49,100
• PEG Ratio: -0.39
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 1.02
• P/FCF Ratio: -137.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: ¥2,305.00 ▲(10.08% Upside)

ASKA Pharmaceutical Holdings shows strong financial performance with solid revenue growth and financial stability, but faces challenges in improving net profit margins and cash flow management. The technical analysis indicates a bearish trend, which could be a concern for short-term investors. Valuation metrics suggest the stock is reasonably priced, with a decent dividend yield providing some appeal.

ASKA Pharmaceutical Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

ASKA Pharmaceutical Holdings Co., Ltd. (4886) is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription drugs and over-the-counter medications. The company operates primarily in the sectors of pharmaceuticals and healthcare, focusing on therapeutic areas such as neurology, oncology, and infectious diseases. ASKA is known for its innovative drug formulations and commitment to improving patient outcomes through advanced medical solutions.

How the Company Makes Money

ASKA Pharmaceutical Holdings generates revenue primarily through the sales of its pharmaceutical products, which include both prescription medications and over-the-counter drugs. The company’s revenue model is based on a combination of direct sales to healthcare providers, pharmacies, and hospitals, as well as partnerships and collaborations with other pharmaceutical firms for joint development and marketing efforts. Significant revenue streams include royalties from patented drugs, sales of proprietary medications, and income from research collaborations with academic institutions and biopharmaceutical companies. Additionally, government contracts and reimbursement from health insurance systems for approved pharmaceuticals contribute to ASKA's earnings.

ASKA Pharmaceutical Holdings Co., Ltd. Financial Statement Overview

Summary

ASKA Pharmaceutical Holdings demonstrates solid revenue growth and financial stability, with strong equity and manageable debt levels. However, there are areas for improvement, particularly in net profit margins and cash flow management. The company should focus on enhancing operational efficiencies and ensuring consistent positive cash flows to support future growth and stability.

Income Statement

ASKA Pharmaceutical Holdings has shown consistent revenue growth over the years, with a substantial increase from 2020 to 2025. The company maintains solid gross profit margins, averaging around 48.5% across the years. However, net profit margins have slightly declined from 12.0% in 2024 to 8.0% in 2025, indicating a need to manage expenses better. The EBIT and EBITDA margins, while healthy, also show room for improvement in maintaining operational efficiency.

Balance Sheet

The company's balance sheet reflects a stable equity position with a debt-to-equity ratio that has improved from 0.35 in 2020 to 0.17 in 2025, indicating a reduction in leverage. The equity ratio has remained strong, maintaining around 65% to 70%, showcasing financial stability. However, the total debt, although reduced, still requires careful management to ensure long-term financial health.

Cash Flow

ASKA Pharmaceutical has faced fluctuating free cash flow, with a significant drop in 2025 compared to 2024. Despite this, the company has managed to maintain a positive operating cash flow to net income ratio, reflecting operational efficiency. The free cash flow to net income ratio indicates that cash reserves are not as robust as needed, emphasizing the need for better cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	67.11B	64.14B	62.84B	60.46B	56.61B	55.18B
Gross Profit	31.79B	31.34B	30.66B	28.59B	26.35B	25.38B
EBITDA	7.45B	8.49B	12.57B	8.53B	9.10B	6.97B
Net Income	5.07B	5.10B	7.54B	4.24B	4.29B	2.71B
Balance Sheet
Total Assets	102.95B	100.53B	90.75B	87.14B	83.30B	82.58B
Cash, Cash Equivalents and Short-Term Investments	7.23B	11.16B	17.24B	17.91B	17.10B	10.51B
Total Debt	13.77B	10.90B	9.48B	12.62B	14.05B	16.39B
Total Liabilities	33.72B	31.34B	28.82B	32.61B	34.41B	38.07B
Stockholders Equity	65.44B	65.31B	61.93B	54.53B	48.89B	44.51B
Cash Flow
Free Cash Flow	0.00	-475.00M	33.00M	2.60B	465.00M	5.44B
Operating Cash Flow	0.00	2.48B	1.49B	3.35B	2.84B	6.54B
Investing Cash Flow	0.00	-6.12B	1.71B	-1.13B	6.74B	-2.87B
Financing Cash Flow	0.00	-2.96B	-3.94B	-1.82B	-3.00B	-455.00M

ASKA Pharmaceutical Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2094.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4886, the sentiment is Negative. The current price of 2094 is below the 20-day moving average (MA) of 2150.45, below the 50-day MA of 2300.82, and below the 200-day MA of 2235.33, indicating a bearish trend. The MACD of -51.24 indicates Positive momentum. The RSI at 37.51 is Neutral, neither overbought nor oversold. The STOCH value of 11.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4886.

ASKA Pharmaceutical Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4554	―	¥38.54B	12.53	7.10%	2.88%	12.06%	-51.89%
4569	―	¥73.96B	7.84	―	3.70%	9.83%	86.18%
4886	―	¥57.64B	12.11	―	2.48%	6.23%	-31.45%
4577	―	¥37.43B	18.93	―	4.22%	7.56%	-48.91%
4534	―	¥100.32B	17.35	4.88%	2.71%	2.74%	36.86%
4538	―	¥18.58B	―	―	3.87%	8.71%	-325.91%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

ASKA Pharmaceutical Holdings Co., Ltd. Corporate Events

ASKA Secures OTC Approval for NORLEVO® Emergency Contraceptive Pill

ASKA Pharmaceutical Co., Ltd., in collaboration with Daiichi Sankyo Healthcare, has obtained marketing authorization for the emergency contraceptive pill NORLEVO® to be sold over-the-counter (OTC) in Japan. This move aims to empower women by enhancing accessibility to reproductive health products, marking a significant milestone in sexual reproductive health and rights. The impact on the company’s financial year 2025 is under evaluation, and further details on product specifications and sales timing will be announced later.

The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2590.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

ASKA Pharmaceutical Maintains Defense Against Potential Share Acquisition

ASKA Pharmaceutical Holdings Co., Ltd. has decided to continue its Response Policy regarding the potential large-scale purchase of its shares by Dalton. Despite Dalton’s withdrawal of its intent to purchase, ASKA remains cautious, citing unresolved concerns that such an acquisition could conflict with the interests of general shareholders and potentially harm the company’s long-term value. The decision reflects ASKA’s commitment to safeguarding shareholder interests and maintaining corporate value.

The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2590.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

ASKA Pharmaceutical Halts Share Purchase Procedures After Dalton Withdrawal

ASKA Pharmaceutical Holdings announced the termination of procedures related to a large-scale purchase of its share certificates following the withdrawal of a statement of intent by Dalton Investments and its affiliates. This decision halts the previously initiated evaluation process by the board of directors and ends the requirement for Dalton to disclose further information, potentially stabilizing ASKA’s market position and operations.

The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2590.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

ASKA Pharmaceutical Reiterates Request for Transparency in Share Purchase

ASKA Pharmaceutical Holdings Co., Ltd. has reiterated its request to Dalton Investments and others to provide necessary information regarding their large-scale purchase of ASKA’s share certificates. Despite guidelines emphasizing transparency in corporate takeovers, Dalton has not complied, leading to concerns about the impact on shareholder decision-making and the company’s strategic options.

The most recent analyst rating on (JP:4886) stock is a Buy with a Yen2732.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

ASKA Pharmaceutical Implements Response to Dalton’s Share Acquisition

ASKA Pharmaceutical Holdings Co., Ltd. has implemented a response policy to address large-scale purchases of its share certificates by Dalton Investments and associated entities. The company is concerned about Dalton’s potential acquisition of a significant minority stake, which could lead to negative control, effectively giving Dalton veto power over company decisions. The response policy aims to ensure that shareholders and the Board of Directors have the necessary information to make informed decisions, but Dalton’s refusal to comply with the information request raises concerns about future compliance and intentions.

The most recent analyst rating on (JP:4886) stock is a Buy with a Yen2732.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

ASKA Pharmaceutical Responds to Large-Scale Share Purchase Intent

ASKA Pharmaceutical Holdings Co., Ltd. has received a statement of intent from Dalton Investments, Nippon Active Value Fund PLC, and NAVF Select LLC regarding a large-scale purchase of the company’s share certificates. In response, ASKA has delivered an information list to these entities, requesting necessary information for shareholders and the board of directors to evaluate the purchase. This move is part of ASKA’s response policy to ensure transparency and informed decision-making in light of potential acquisition implications.

The most recent analyst rating on (JP:4886) stock is a Buy with a Yen2849.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

ASKA Pharmaceutical Receives Large-scale Purchase Intent from Dalton Investments

ASKA Pharmaceutical Holdings Co., Ltd. has received a statement of intent from Dalton Investments and associated entities to potentially purchase up to 30% of the company’s shares. This move could lead to proposals aimed at enhancing corporate value and shareholder interests, with the possibility of delisting the company if deemed beneficial. The company’s board plans to review the terms of this large-scale purchase and will provide necessary information to shareholders for consideration.

The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

ASKA Pharmaceutical Completes Treasury Share Disposal for Remuneration

ASKA Pharmaceutical Holdings Co., Ltd. has completed the payment procedures for the disposal of 32,700 treasury shares as restricted share remuneration. This move, resolved by the Board of Directors, involves a total disposal amount of 77,400,900 yen and is aimed at compensating corporate officers and board members, potentially impacting the company’s financial structure and stakeholder interests.

The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

ASKA Pharmaceutical Reports Q1 FY2025 Financial Results with Increased Sales but Declining Profits

ASKA Pharmaceutical Holdings Co., Ltd. reported its consolidated financial results for the first quarter of FY2025, showing an 18.2% increase in net sales compared to the previous year. However, the company experienced declines in operating profit, ordinary profit, and profit attributable to owners of the parent, indicating challenges in maintaining profitability. Despite these challenges, ASKA’s financial position remains stable with a slight increase in total assets. The company maintains its forecast for the full fiscal year, expecting significant growth in operating profit and ordinary profit, which suggests a positive outlook for stakeholders.

The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.

ASKA Pharmaceutical Reports Strong Sales Growth Amid Rising R&D Costs

ASKA Pharmaceutical Holdings Co., Ltd. reported a significant increase in sales for the first quarter of FY2025, driven by strong domestic performance and contributions from overseas operations. Despite the rise in sales, the company’s operating profit decreased due to higher costs associated with R&D and expanded business activities. The financial forecast for FY2025 remains unchanged, with expectations of continued growth in net sales and operating profit.

The most recent analyst rating on (JP:4886) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on ASKA Pharmaceutical Holdings Co., Ltd. stock, see the JP:4886 Stock Forecast page.